Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature.
head and neck
multidisciplinary team
radiation-induced cancer
radiotherapy
second primary tumour
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
14 07 2023
14 07 2023
Historique:
received:
31
05
2023
revised:
10
07
2023
accepted:
12
07
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Radiation therapy (RT) is a mainstay for the treatment of head and neck (HN) cancers, with 80% of patients receiving such treatment. Radiation-induced malignancies represent a life-threatening long-term effect of RT, with an incidence of 0.5% to 15%. After 13 years, a 33-year-old woman treated with chemo-radiotherapy for nasopharyngeal carcinoma developed a locally advanced, radiation-induced, p16-negative oropharyngeal squamous cell carcinoma (SCC) at the base of the tongue. Chemo/immunotherapy was administered as a first-line treatment. Given the optimal response and the feasibility of surgery, after three cycles, the patient underwent a total glossectomy, bilateral neck dissection, and reconstruction with a thoraco-dorsal free flap. A histological examination found SCC with a residual cancer burden of 70% and free margins. The mechanisms responsible for carcinogenesis after RT are still not completely clear. Diagnosis may be challenging due to the previous treatment; growth patterns are unusual, and lymphotropism is lower. Prognosis is usually poor since surgical resectability is often not achievable. Radiation-induced malignancies are difficult to treat. Patient management should always be discussed at a multidisciplinary level. Future research is needed to assess whether the promising results of clinical studies with pre-operative immunotherapy in locally advanced HN SCC patients may be translated into radiation-induced cancers.
Sections du résumé
BACKGROUND
Radiation therapy (RT) is a mainstay for the treatment of head and neck (HN) cancers, with 80% of patients receiving such treatment. Radiation-induced malignancies represent a life-threatening long-term effect of RT, with an incidence of 0.5% to 15%.
CASE DESCRIPTION
After 13 years, a 33-year-old woman treated with chemo-radiotherapy for nasopharyngeal carcinoma developed a locally advanced, radiation-induced, p16-negative oropharyngeal squamous cell carcinoma (SCC) at the base of the tongue. Chemo/immunotherapy was administered as a first-line treatment. Given the optimal response and the feasibility of surgery, after three cycles, the patient underwent a total glossectomy, bilateral neck dissection, and reconstruction with a thoraco-dorsal free flap. A histological examination found SCC with a residual cancer burden of 70% and free margins.
DISCUSSION
The mechanisms responsible for carcinogenesis after RT are still not completely clear. Diagnosis may be challenging due to the previous treatment; growth patterns are unusual, and lymphotropism is lower. Prognosis is usually poor since surgical resectability is often not achievable.
CONCLUSIONS
Radiation-induced malignancies are difficult to treat. Patient management should always be discussed at a multidisciplinary level. Future research is needed to assess whether the promising results of clinical studies with pre-operative immunotherapy in locally advanced HN SCC patients may be translated into radiation-induced cancers.
Identifiants
pubmed: 37504352
pii: curroncol30070492
doi: 10.3390/curroncol30070492
pmc: PMC10378216
doi:
Types de publication
Review
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
6708-6719Références
Oral Oncol. 2020 Jun 27;109:104863
pubmed: 32604060
Otolaryngol Head Neck Surg. 2016 May;154(5):880-7
pubmed: 26956200
Nat Commun. 2021 Dec 22;12(1):7348
pubmed: 34937871
Chin J Cancer. 2016 Oct 12;35(1):89
pubmed: 27729091
Head Neck. 2022 Feb;44(2):562-571
pubmed: 34825751
Oral Oncol. 2005 Mar;41(3):225-43
pubmed: 15743686
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152
pubmed: 32665297
Cancer Treat Rev. 2017 Sep;59:79-92
pubmed: 28759822
Front Oncol. 2018 Oct 17;8:449
pubmed: 30386739
J Cancer Surviv. 2023 Aug;17(4):1082-1093
pubmed: 36350483
Int J Oral Maxillofac Surg. 2023 May 20;:
pubmed: 37217386
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2021 Apr 15;13(8):
pubmed: 33920762
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):951-61
pubmed: 10571202
Head Neck. 2015 Jun;37(6):815-22
pubmed: 24623597
Curr Opin Otolaryngol Head Neck Surg. 2022 Apr 1;30(2):161-167
pubmed: 34670257
Cancer. 1948 May;1(1):3-29
pubmed: 18867438
Curr Opin Oncol. 2022 May 1;34(3):185-195
pubmed: 35256551
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221150559
pubmed: 36683526
Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):449-56
pubmed: 2674073
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
NPJ Precis Oncol. 2019 Sep 27;3:22
pubmed: 31583278
Head Neck. 2014 Feb;36(2):209-14
pubmed: 23729214
Ann Oncol. 2014 Feb;25(2):462-6
pubmed: 24401930
Front Oncol. 2020 Dec 02;10:566315
pubmed: 33344227
J Oral Maxillofac Surg. 2017 Oct;75(10):2235-2241
pubmed: 28351659
Otolaryngol Head Neck Surg. 2004 Nov;131(5):643-5
pubmed: 15523441
Radiother Oncol. 2021 Mar;156:281-293
pubmed: 33515668
Ann Oncol. 2008 Jun;19(6):1180-6
pubmed: 18238781
Cancer. 2020 Aug 1;126(15):3560-3568
pubmed: 32426866
Cancer Epidemiol Biomarkers Prev. 2022 May 4;31(5):1119-1129
pubmed: 35391491
Clin Cancer Res. 2022 Mar 01;28(5):915-927
pubmed: 34911681
Clin Cancer Res. 2020 Feb 1;26(3):545-551
pubmed: 31672770
Curr Oncol Rep. 2021 Aug 27;23(11):129
pubmed: 34453267
Oral Dis. 2023 May 22;:
pubmed: 37213085
Cancer. 2006 Sep 15;107(6):1287-93
pubmed: 16909425
Lancet Oncol. 2021 May;22(5):727-736
pubmed: 33862002
Otolaryngol Head Neck Surg. 2017 Aug;157(2):252-259
pubmed: 28397585
Acta Oncol. 2014 Aug;53(8):1041-7
pubmed: 24983652